<<
-
SESSION I
-
Aldosterone Receptor antagonists clinical interest: Beyond the “Aldosterone escape” concept
-
Relationship between Aldosterone and clinical parameters in dogs with Mitral Valve Disease
-
Where are we with aldosterone escape (Break-through) in 2011?
-
SESSION I
-
SESSION II
-
Targeting the Aldosterone pathway in cardiovascular disease
-
Treatment of preserved cardiac function heart failure with an Aldosterone antagonist: the NHLBI TOPCAT Trial
-
The DELAY STUDY (DElay of Appearance of sYmptoms of canine degenerative mitral valve disease treated with Spironolactone and Benazepril)
-
SESSION II
-
SESSION III
-
How to use biomarkers in cardiology ?
-
Potential markers of cardiac remodeling and function
-
SESSION III
-
SESSION IV
-
A rock and a hard place: cardiorenal syndrome in clinical canine veterinary patients
-
Cardio-Renal syndromes: Lessons from Human pathophysiology
-
Mineralocorticoid receptor antogonists: New therapeutic opportunities in chronic kidney diseases
-
SESSION IV
-
Conclusion to CardioSymposium 2011
-
Introduction to Symposium
>>
